Chlamydia antigens
US-9675683-B2 · Jun 13, 2017 · US
Vaccine composition against Chlamydiaceae infections
US11229691B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11229691-B2 |
| Application number | US-202016884649-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 27, 2020 |
| Priority date | Jul 28, 2015 |
| Publication date | Jan 25, 2022 |
| Grant date | Jan 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating infections caused by Chlamydia bacteria selected in the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis , comprising: administering to a subject in need thereof a composition comprising a therapeutically effective amount of an inactivated BL form of Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis, wherein the inactivated BL form of Chlamydia bacteria has been previously inactivated by treating with a β-lactam, wherein the β-lactam is selected from the group consisting of amoxicillin, benzylpenicillin, phenoxymethylpenicillin, cloxacillin, cefadroxil, cefixime, imipenem, mecillinam, clavulanic acid, tazobactam, sulbactam, and the combination of cefixime and imipenem. 2. The method of claim 1 , wherein said β-lactam is penicillin G. 3. The method of claim 1 , wherein Chlamydia bacteria is Chlamydia trachomatis or Chlamydia muridarum. 4. The method of claim 1 , wherein a pathology caused by the infection with Chlamydia bacteria is an ocular pathology, a genital pathology, a respiratory pathology, a cardiovascular dysfunction, a circulatory dysfunction, a joint disease, or an inflammatory disease. 5. The method of claim 4 , wherein said genital pathology is selected from the group consisting of venereal lymphogranuloma, urethritis, orchiepididymitis, cervicovaginitis, cervicitis, endocervicitis, endometritis, perihepatitis and salpingitis.
Assignees
Inventors
Classifications
inactivated (killed) · CPC title
Infectious diseases, e.g. generalised sepsis · CPC title
- A61K39/118Primary
Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci · CPC title
Antibacterial agents · CPC title
Chlamydia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11229691B2 cover?
- The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Univ Paris Diderot Paris 7, Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification A61K39/118. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).